FUNDAMENTALS
EdgeFII/DII
DRREDDYDR. Reddy's Laboratories
₹1,390.20-0.76%
Terminal
  • Overview
  • Price
  • Ratios
  • About
  • P&L
  • Balance
  • Cash flow
  • Holders
  • Actions
  • Peers
  • News
DRREDDYNSE · EquityPharmaceuticals

DR. Reddy's Laboratories

ISIN
INE089A01031
Instrument key
NSE_EQ|INE089A01031
Open in terminal Fundamentals cached for 6 hours
Last traded price
₹1,390.20-10.70 · -0.76%
Day rangecircuit ₹1,251.20 – ₹1,529.20
1,384.80
1,400.00

as of 21/11/2026, 4:12:47 pm

Open
₹1,388.00
Day high
₹1,400.00
Day low
₹1,384.80
Prev. close
₹1,400.90
Volume
8.31 L
VWAP
₹1,392.27

On this page

Company

  • Overview
  • Price chart
  • Key ratios
  • About

Statements

  • Profit & loss
  • Balance sheet
  • Cash flow

Ownership

  • Shareholding
  • Corporate actions
  • Peers

Market

  • News

02/Price history

Price chart

1 month · 30-minute candles. Hover the chart for the OHLC of any candle; the table below holds the same data row by row.

1D1W1M6M1Y5YMAX
Change · 1M
+13.72%
1,222.50 → 1,390.20
Period high
₹1,406.10
18/11/2026
Period low
₹1,212.70
22/10/2026
From high
-1.13%
+14.64% from low
Avg volume
1.58 L
4.37 Cr total
Candles
276
141 up / 129 down
20 Nov 2026O 1,388.00H 1,390.20L 1,388.00C 1,390.20Vol 42.5K
SMA 20SMA 50Averages need 50 candles before they begin
Candle data276 rows of open, high, low, close and volumeShowHide
20 Nov 20261,388.001,390.201,388.001,390.20+0.16%2.2042.5K
20 Nov 20261,389.701,391.001,387.501,388.00-0.12%3.5077.9K
20 Nov 20261,389.901,390.801,385.601,389.80-0.01%5.2040.9K
20 Nov 20261,393.601,394.501,389.501,390.20-0.24%5.0079.4K
20 Nov 20261,392.601,395.001,392.501,393.20+0.04%2.5042.9K
20 Nov 20261,391.201,393.401,388.701,392.60+0.10%4.7043.8K
20 Nov 20261,393.101,395.901,389.301,390.50-0.19%6.6053.8K
20 Nov 20261,387.201,395.001,386.501,392.70+0.40%8.5090.4K
20 Nov 20261,391.001,394.201,386.201,387.00-0.29%8.0064.9K
20 Nov 20261,394.601,395.001,389.701,391.00-0.26%5.3088.0K

Historical price and volume data · Showing 1–10 of 276

1 / 28

03/Valuation & returns

Key ratios vs sector

Company value benchmarked against the sector median. The ratio set is sector specific — banks report NIM, CASA and Net NPA instead of EV/EBITDA.

P/E

Price ÷ earnings per share

42.09
Company
42.09
Sector
-45.02

Worse than sector by 193%

P/B

Price ÷ book value per share

2.99
Company
2.99
Sector
4.21

Better than sector by 29%

ROA

Net income ÷ total assets

4.79%
Company
4.79%
Sector
1.19%

Better than sector by 303%

ROE

Net income ÷ shareholders' equity

7.21%
Company
7.21%
Sector
-0.4%

Better than sector by 1902%

ROCE

EBIT ÷ capital employed

8.58%
Company
8.58%
Sector
15.44%

Worse than sector by 44%

Quick Ratio

Liquid assets ÷ current liabilities

1.35
Company
1.35
Sector
4.8

Worse than sector by 72%

EV/EBITDA

Enterprise value ÷ EBITDA

19.73
Company
19.73
Sector
22.86

Better than sector by 14%

04/Business

About the company

Sector: Pharmaceuticals

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

Sector market cap (INR)
₹1,16,145 Cr

reported in crore

Sector market cap (USD)
$12.90B

reported in billion

Market capitalisation is reported at the sector-constituent level, not the standalone company level.

05/Profit & loss

Consolidated income statement

Quarterly figures in ₹ crore. Growth marked reported is provided; margins are derived.

YearlyQuarterly
ConsolidatedStandalone
Revenue · Sep 2026
₹8,854 Cr
+4.73% vs Jun 2026
Net profit · Sep 2026
₹913 Cr
+109.64% vs Jun 2026
Operating margin
13.9%
was 6.5%
Revenue CAGR · 4p
-0.6%
profit -8.4% · op -7.3%
Filed order
Revenue8,8548,4558,0229,022
Revenue growthreported4.7%5.4%-11.1%—
Operating profit1,2285532001,543
Operating profit growthreported121.9%177.1%-87.1%—
Operating marginderived13.9%6.5%2.5%17.1%
Net profit9134362211,190
Net profit growthreported109.6%96.8%-81.4%—
Net marginderived10.3%5.2%2.8%13.2%
EPS — basic₹/share, annual——50.41—

Figures in ₹ crore. Margin rows are computed from the reported values.

Full annual line itemsRevenue, other income, expenses, tax, EPSShowHide
Filed order
Revenue33,70032,64428,01124,670
Other Income1,3581,0978941,056
Total Revenue35,05933,74128,90525,725
Total Expenses29,67926,08321,71919,714
Profit Before Tax5,3937,6807,2016,049
Tax1,2351,9541,6231,541
Profit After Tax4,1585,7255,5784,507
EPS - Basic50.4167.8967.04271.47
EPS - Diluted50.3567.7966.92270.90

This breakdown is available annually, even when the summary above is quarterly. EPS rows are per share.

06/Balance sheet

Consolidated balance sheet

Only annual balance sheets are available — the quarterly filter does not apply here. Figures in ₹ crore; net worth is assets minus liabilities.

ConsolidatedStandalone
Total assets · Mar 2026
₹58,123 Cr
+17.60% YoY
Total liabilities
₹19,893 Cr
Net worth
₹38,231 Cr
Liabilities ÷ assets
34.2%
lower means a lighter balance sheet
Filed order
Total assets58,12349,42738,86432,285
Total liabilities19,89315,49910,6098,999
Net worthderived38,23133,92728,25523,286
Liabilities ÷ assetsderived34.2%31.4%27.3%27.9%
Asset growthderived17.6%27.2%20.4%—

Figures in ₹ crore. Stacked chart height equals total assets.

Full annual line itemsNon-current & current assets, liabilities, equity capitalShowHide
Filed order
Non-Current Assets27,94424,40914,05911,860
Current Assets30,17925,01824,80520,426
Total Assets58,12349,42738,86432,285
Current Liabilities16,74713,0349,5888,572
Net Current Asset13,43211,98415,21711,853
Non-Current Liabilities3,1452,4651,021427
Equity Capital38,23133,92728,25523,286
Total Equity & Liabilities58,12349,42738,86432,285

Figures in ₹ crore unless the line item is per-share.

07/Cash flow

Consolidated cash flow

Annual only, in ₹ crore. Negative values are outflows, so healthy companies usually show positive operating and negative investing cash flow.

ConsolidatedStandalone
Operating · Mar 2026
₹5,674 Cr
+22.20% YoY
Investing
-₹6,549 Cr
Financing
₹829 Cr
Free cash flow
-₹876 Cr
operating + investing
Filed order
Operating activities5,6744,6434,5435,888
Operating changereported22.2%2.2%-22.8%—
Investing activities-6,549-5,808-4,028-4,137
Investing changereported-12.8%-44.2%2.6%—
Financing activities8291,891-376-2,686
Financing changereported-56.2%602.5%86.0%—
Net cash flowderived-47726139-936
Free cash flowoperating + investing-876-1,1655151,750

Figures in ₹ crore.

Full annual line itemsProfit before tax through closing cash balanceShowHide
Filed order
Profit before tax5,3937,6807,2016,049
Income before WC changes8,1019,6418,5667,744
Change in Assets-1,532-2,304-2,650-841
Change in Liabilities458-69563255
Change in WC-1,075-2,999-2,018-785
Cash flow from Operations5,6744,6434,5435,888
Cash flow from Investing-6,549-5,808-4,028-4,137
Cash flow from Financing8291,891-376-2,686
Total Cash Flow-47726139-936
Cash (Start of the year)1,4597115781,485
Cash (End of the year)1,5371,459711578

Figures in ₹ crore unless the line item is per-share.

08/Ownership

Shareholding pattern

Percentage of total shares by holder category across the last 4 reported quarters. Sort any quarter column to rank holders by size.

Promoters
26.63%
-0.01 pts QoQ
FII
31.39%
-0.68 pts QoQ
DII (other)
17.74%
-0.84 pts QoQ
Mutual funds
14.14%
+0.98 pts QoQ
Retail & others
10.10%
+0.55 pts QoQ
Filed order
Promoters26.6%26.6%26.6%26.6%
FII31.4%32.1%33.1%33.2%
DII (other)17.7%18.6%17.5%16.6%
Mutual funds14.1%13.2%13.2%13.9%
Retail & others10.1%9.6%9.6%9.7%
Promoters — QoQ changepts, derived-0.0%0.0%-0.0%—
FII — QoQ changepts, derived-0.7%-1.0%-0.1%—
DII (other) — QoQ changepts, derived-0.8%1.1%0.9%—
Mutual funds — QoQ changepts, derived1.0%-0.0%-0.7%—
Retail & others — QoQ changepts, derived0.5%-0.0%-0.2%—
Totalderived100.0%100.0%100.0%100.0%

Values are percentages of total outstanding shares; QoQ rows are percentage-point moves.

09/Events

Corporate actions

Dividends, bonuses, splits and rights issues. Filter by type, sort by any date, and expand a row for the full event detail.

DividendFinal₹8.00800.0%10 Jul 202610 Jul 202612 May 2026

10/Comparison

Peers & competitors

Competitor set priced live. Filter by sector, sort any column, and expand a peer for its business description.

SUNPHARMASUN Pharmaceutical IND LPharmaceuticals₹1,884.90-0.79%19.16 L₹4,52,299 Cr$50.26B
DIVISLABDivi S Laboratories LtdPharmaceuticals₹11,180.50+0.02%4.05 L₹2,97,325 Cr$33.04B
TORNTPHARMTorrent Pharmaceuticals LPharmaceuticals₹4,689.50+1.70%2.00 L₹1,78,727 Cr$19.86B
LAURUSLABSLaurus Labs LimitedPharmaceuticals₹2,294.60-0.49%8.79 L₹1,24,002 Cr$13.78B
ZYDUSLIFEZydus Lifesciences LtdPharmaceuticals₹1,200.00-0.24%7.80 L₹1,19,207 Cr$13.25B
CIPLACipla LtdPharmaceuticals₹1,415.00-0.25%14.84 L₹1,14,312 Cr$12.70B
MANKINDMankind Pharma LimitedPharmaceuticals₹2,665.00+1.37%4.56 L₹1,09,870 Cr$12.21B
AUROPHARMAAurobindo Pharma LtdPharmaceuticals₹1,799.00-0.37%8.11 L₹1,03,298 Cr$11.48B
LUPINLupin LimitedPharmaceuticals₹2,014.00+0.76%6.31 L₹91,916 Cr$10.21B
GLENMARKGlenmark PharmaceuticalsPharmaceuticals₹2,648.00+1.51%5.40 L₹74,733 Cr$8.30B

Market cap is the sector-constituent figure reported per peer · Showing 1–10 of 10

1 / 1

11/Coverage

Company news

Articles published in the last seven days, paginated by the provider.

No news in the last seven days

Company news is available for a rolling one-week window.